Evidence-based Guideline: Diagnosis and Treatment of Limb-Girdle Muscular Dystrophy

e118. Yuan WL, Huang CY, Wang JF, et al. R25G mutation in exon 1 of LMNA gene is associated with dilated cardiomyopathy and limb-girdle muscular dystrophy 1B. Chin Med J (Engl) 2009;122:2840–2845.

e119. De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002;70:726–736.

e120. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998;18(4):365–368.

e121. Aboumousa A, Hoogendijk J, Charlton R, et al. Caveolinopathy--new mutations and additional symptoms. Neuromuscul Disord 2008;18(7):572–578.

e122. González-Pérez P, Gallano P, González-Quereda L, et al. Phenotypic variability in a Spanish family with a Caveolin-3 mutation. J Neurol Sci 2009;276:95–98.

e123. Cagliani R, Bresolin N, Prelle A, et al. A CAV3 microdeletion differentially affects skeletal muscle and myocardium. Neurology 2003;61:1513–1519.

e124. Catteruccia, M, Sanna T, Santorelli FM, et al. Rippling muscle disease and cardiomyopathy associated with a mutation in the CAV3 gene. Neuromuscul Disord 2009;19:779–783.

e125. Dotti MT, Malandrini A, Gambelli S, Salvadori C, De Stefano N, Federico A. A new missense mutation in caveolin-3 gene causes rippling muscle disease. J Neurol Sci 2006;243:61–64.

e126. Fischer D, Schroers A, Blümcke I, et al. Consequences of a novel caveolin-3 mutation in a large German family. Ann Neurol 2003;53:233–241.

e127. Fulizio L, Nascimbeni AC, Fanin M, et al. Molecular and muscle pathology in a series of caveolinopathy patients. Hum Mutat 2005;25:82–89.

e128. Jacobi C, Ruscheweyh R, Vorgerd M, Weber MA, Storch-Hagenlocher B, Meinck HM. Rippling muscle disease: variable phenotype in a family with five afflicted members. Muscle Nerve 2010;41:128–132.

e129. Ricker K, Moxley RT, Rohkamm R. Rippling muscle disease. Arch Neurol 1989;46:405–408.

e130. Sundblom J, Stålberg E, Osterdahl M, et al. Bedside diagnosis of rippling muscle disease in CAV3 p.A46T mutation carriers. Muscle Nerve 2010;41:751–757.

e131. Vorgerd M, Bolz H, Patzold T, Kubisch C, Malin JP, Mortier W. Phenotypic variability in rippling muscle disease. Neurology 1999;52:1453–1459.

e132. Yabe I, Kawashima A, Kikuchi S, et al. Caveolin-3 gene mutation in Japanese with rippling muscle disease. Acta Neurol Scand 2003;108:47–51.

e133. Hackman P, Sandell S, Sarparanta J, et al. Four new Finnish families with LGMD1D; refinement of the clinical phenotype and the linked 7q36 locus. Neuromuscul Disord 2011;21:338–344.

e134. Sarparanta J, Jonson PH, Golzio C, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 2012;44:450–455, S1–S2.

e135. Harms MB, Sommerville RB, Allred P, et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol 2012;71:407–416.

e136. Urtasun M, Sáenz A, Roudaut C, et al. Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain). Brain 1998;121:1735–1747.

e137. Angelini C, Nardetto L, Borsato C, et al. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res 2010;32:41–46.

e138. Balci B, Aurino S, Haliloglu G, et al. Calpain-3 mutations in Turkey. Eur J Pediatr 2006; 165:293–298.

e139. Beckmann JS, Richard I, Hillaire D, et al. A gene for limb-girdle muscular dystrophy maps to chromosome 15 by linkage. C R Acad Sci III 1991;312:141–148.

e140. Blázquez L, Azpitarte M, Sáenz A, et al. Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis. Neurogenetics 2008;9:173–182.

e141. Charlton R, Henderson M, Richards J, et al. Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Neuromuscul Disord 2009;19:449–457.

e142. Chrobáková T, Hermanová M, Kroupová I, et al. Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome. Neuromuscul Disord 2004;14:659–665.

e143. de Paula F, Vainzof M, Passos-Bueno MR, et al. Clinical variability in calpainopathy: what makes the difference? Eur J Hum Genet 2002;10:825–832.

e144. Degardin A, Morillon D, Lacour A, Cotten A, Vermersch P, Stojkovic T. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol 2010;39(12):1219–1227.

e145. Fanin M, Nardetto L, Nascimbeni AC, et al. Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A. J Med Genet 2007;44(10):609–614.

e146. Fanin M, Nascimbeni AC, Angelini C. Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations. J Med Genet 2007;44:38–43.

e147. Fanin M, Pegoraro E, Matsuda-Asada C, Brown RH Jr, Angelini C. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. Neurology 2001;56:660–665.

e148. Fardeau M, Hillaire D, Mignard C, et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996;119:295–308.

e149. Fischer D, Walter MC, Kesper K, et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 2005;252:538–547.

e150. Groen E, Charlton R, Barresi R, et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 2007;130:3237–3249.

e151. Kawai H, Akaike M, Kunishige M, et al. Clinical, pathological, and genetic features of limb-girdle muscular dystrophy type 2A with new calpain 3 gene mutations in seven patients from three Japanese families. Muscle Nerve 1998;21:1493–1501.

e152. Mercuri E, Bushby K, Ricci E, et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005;15:164–171.

e153. Minami N, Nishino I, Kobayashi O, Ikezoe K, Goto Y, Nonoka I. Mutations of calpain 3 gene in patients with sporadic limb-girdle muscular dystrophy in Japan. J Neurol Sci 1999;171:31–37.

e154. Schessl J, Walter MC, Schreiber G, et al. Phenotypic variability in siblings with calpainopathy (LGMD2A). Acta Myol 2008;27:54–58.

e155. Stramare R, Beltrame V, Dal Borgo R, et al. MRI in the assessment of muscular pathology: a comparison between limb-girdle muscular dystrophies, hyaline body myopathies and myotonic dystrophies. Radiol Med 2010;115:585–599.

e156. Sveen ML, Thune JJ, Køber L, Vissing J. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. Arch Neurol 2008;65:1196–1201.

e157. Topaloğlu H, Dinçer P, Richard I, et al. Calpain-3 deficiency causes a mild muscular dystrophy in childhood. Neuropediatrics 1997;28:212–216.

e158. Pollitt C, Anderson LV, Pogue R, Davison K, Pyle A, Bushby KM. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromuscul Disord 2001;11:287–296.

e159. Starling A, de Paula F, Silva H, Vainzof M, Zatz M. Calpainopathy: how broad is the spectrum of clinical variability? J Mol Neurosci 2003;21:233–236.

e160. Amato AA. Adults with eosinophilic myositis and calpain-3 mutations. Neurology 2008;70:730–731.

e161. Choi ER, Park SJ, Choe YH, et al. Early detection of cardiac involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:31.

e162. Aoki M, Liu J, Richard I, et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001;57:271–278.

e163. Argov Z, Sadeh M, Mazor K, et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 2000;123:1229–1237.

e164. Comerlato EA, Scola RH, Werneck LC. Limb-girdle muscular dystrophy: an immunohistochemical diagnostic approach. Arq Neuropsiquiatr 2005;63(2A):235–245.

e165. Cupler EJ, Bohlega S, Hessler R, McLean D, Stigsby B, Ahmad J. Miyoshi myopathy in Saudi Arabia: clinical, electrophysiological, histopathological and radiological features. Neuromuscul Disord 1998;8:321–326.

e166. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol 2002;28:461–470.

e167. Khadilkar S, Singh RK, Kulkarni KS, Chitale AR. A study of clinical and laboratory features of 14 Indian patients with dysferlinopathy. J Clin Neuromuscul Dis 2004;6:1–8.

e168. Klinge L, Aboumousa A, Eagle M, et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 2010;81:946–953.

e169. McNally EM, Ly CT, Rosenmann H, et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet 2000;91:305–312.

e170. Pradhan S. Clinical and magnetic resonance imaging features of ‘diamond on quadriceps’ sign in dysferlinopathy. Neurol India 2009;57:172–175.

e171. Prelle A, Sciacco M, Tancredi L, et al. Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency. Acta Neuropathol 2003;105:537–542.

e172. Ro LS, Lee-Chen GJ, Lin TC, et al. Phenotypic features and genetic findings in 2 chinese families with Miyoshi distal myopathy. Arch Neurol 2004;61:1594–1599.

e173. Rosales XQ, Gastier-Foster JM, Lewis S, et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010;42:14–21.

e174. Takahashi T, Aoki M, Tateyama M, et al. Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology 2003;60:1799–1804.

e175. Ueyama H, Kumamoto T, Nagao S, et al. A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy. Neuromuscul Disord 2001;11:139–145.

e176. Vainzof M, Anderson LV, McNally EM, et al. Dysferlin protein analysis in limb-girdle muscular dystrophies. J Mol Neurosci 2001;17:71–80.

e177. Vilchez JJ, Gallano P, Gallardo E, et al. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Arch Neurol 2005;62:1256–1259.

e178. Weiler T, Greenberg CR, Nylen E, et al. Limb-girdle muscular dystrophy and Miyoshi myopathy in an aboriginal Canadian kindred map to LGMD2B and segregate with the same haplotype. Am J Hum Genet 1996;59:872–878.

e179. Anderson LV, Harrison RM, Pogue R, et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000;10:553–559.

e180. Angelini C, Peterle E, Gaiani A, Bortulussi L, Borsato C. Dysferlinopathy course and sportive activity: clues for possible treatment. Acta Myol 2011;30:127–132.

e181. Brunn A, Schröder R, Deckert M. The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex. Acta Neuropathol 2006;112:325–332.

e182. Cagliani R, Fortunato F, Giorda R, et al. Molecular analysis of LGMD-2B and MM patients: identification of novel DYSF mutations and possible founder effect in the Italian population. Neuromuscul Disord 2003;13:788–795.

e183. Cagliani R, Magri F, Toscano A, et al. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat 2005;26:283.

e184. Cenacchi G, Fanin M, De Giorgi LB, Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005;58:190–195.

e185. Leshinsky-Silver E, Argov Z, Rozenboim L, et al. Dysferlinopathy in the Jews of the Caucasus: a frequent mutation in the dysferlin gene. Neuromuscul Disord 2007;17:950–954.

e186. Cho H, Sung DH, Kim EJ, Yoon CH, Ki CS, Kim JW. Clinical and genetic analysis of Korean patients with Miyoshi myopathy: identification of three novel mutations in the DYSF gene. J Korean Med Sci 2006;21:724–727.

e187. Gallardo E, Rojas-García R, de Luna N, Pou A, Brown RH Jr, Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001;57:2136–2138.

e188. Gayathri N, Alefia R, Nalini A, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol 2011;54:350–354.

e189. Paradas C, Llauger J, Diaz-Manera J, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010;75:316–323.

e190. Kawabe K, Goto K, Nishino I, Angelini C, Hayashi YK. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy. Eur J Neurol 2004;11:657–661.

e191. Kesper K, Kornblum C, Reimann J, Lutterbey G, Schröder R, Wattjes MP. Pattern of skeletal muscle involvement in primary dysferlinopathies: a whole-body 3.0-T magnetic resonance imaging study. Acta Neurol Scand 2009;120:111–118.

e192. Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat 2005;26:165.

e193. Park YE, Kim HS, Lee CH, Nam TS, Choi YC, Kim DS. Two common mutations (p.GIn832X and c.663+1G>C) account for about a third of the DYSF mutations in Korean patients with dysferlinopathy. Neuromuscul Disord 2012;22:505–510.

e194. Piccolo F, Moore SA, Ford GC, Campbell KP. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb--girdle muscular dystrophies. Ann Neurol 2000;48:902–912.

e195. Pradhan S. Calf-head sign in Miyoshi myopathy. Arch Neurol 2006;63:1414–1417.

e196. Weiler T, Bashir R, Anderson LV, et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 1999;8:871–877.

e197. Rosales XQ, Moser SJ, Tran T, et al. Cardiovascular magnetic resonance of cardiomyopathy in limb girdle muscular dystrophy 2B and 2I. J Cardiovasc Magn Reson 2011;13:39.

e198. Saito A, Higuchi I, Nakagawa M, et al. Miyoshi myopathy patients with novel 5' splicing donor site mutations showed different dysferlin immunostaining at the sarcolemma. Acta Neuropathol 2002;104:615–620.

e199. Shunchang S, Fan Q, Huacheng W, et al. Dysferlin mutation in a Chinese pedigree with Miyoshi myopathy. Clin Neurol Neurosurg 2006;108:369–373.

e200. Spuler S, Carl M, Zabojszcza J, et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 2008;63:323–328.

e201. Vernengo L, Oliveira J, Krahn M, et al. Novel ancestral Dysferlin splicing mutation which migrated from the Iberian peninsula to South America. Neuromuscul Disord 2011;21:328–337.

e202. Liewluck T, Pongpakdee S, Witoonpanich R, et al. Novel DYSF mutations in Thai patients with distal myopathy. Clin Neurol Neurosurg 2009;111:613–618.

e203. Brummer D, Walter MC, Palmbach M, et al. Long-term MRI and clinical follow-up of symptomatic and presymptomatic carriers of dysferlin gene mutations. Acta Myol 2005;24:6–16.

e204. Wenzel K, Geier C, Qadri F, et al. Dysfunction of dysferlin-deficient hearts. J Mol Med (Berl) 2007;85:1203–1214.

e205. Mahjneh I, Marconi G, Bushby K, Anderson LV, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord 2001;11:20–26.

e206. Illarioshkin SN, Ivanova-Smolenskaya IA, Tanaka H, et al. Clinical and molecular analysis of a large family with three distinct phenotypes of progressive muscular dystrophy. Brain 1996;119:1895–1909.

e207. Illa I, Serrano-Munuera C, Gallardo E, et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001;49:130–134.

e208. Kefi M, Amouri R, Driss A, et al. Phenotype and sarcoglycan expression in Tunisian LGMD 2C patients sharing the same del521-T mutation. Neuromuscul Disord 2003;13:779–787.

e209. Todorova A, Tournev I, Ninova N, Georgieva V, Kremensky I. Screening for C283Y gamma-sarcoglycan mutation in a high-risk group of Bulgarian Gypsies: evidence for a geographical localization and a non-random distribution among Gypsy subgroups. Community Genet 2002;5:217–221.

e210. Bönnemann CG, Wong J, Jones KJ, et al. Primary gamma-sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile. Neuromuscul Disord 2002;12:273–280.

e211. Calvo F, Teijeira S, Fernandez JM, et al. Evaluation of heart involvement in gamma-sarcoglycanopathy (LGMD2C). A study of ten patients. Neuromuscul Disord 2000;10:560–566.

e212. Duncan D, Kang PB, Rabbat JC, et al. A novel mutation in two families with limb-girdle muscular dystrophy type 2C. Neurology 2006;67:167–169.

e213. Klinge L, Dekomien G, Aboumousa A, et al. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype? Neuromuscul Disord 2008;18(12):934–941.

e214. Lasa A, Piccolo F, de Diego C, et al. Severe limb girdle muscular dystrophy in Spanish gypsies: further evidence for a founder mutation in the gamma-sarcoglycan gene. Eur J Hum Genet 1998;6:396–399.

e215. Leal GF, da-Silva EO. Limb-girdle muscular dystrophy with apparently different clinical courses within sexes in a large inbred kindred. J Med Genet 1999;36:714–718.

e216. Merlini L, Kaplan JC, Navarro C, et al. The limb-girdle muscular dystrophy 2C in Gypsies. Acta Myol 2001;20:188–191.

e217. van der Kooi AJ, de Visser M, van Meegen M, et al. A novel gamma-sarcoglycan mutation causing childhood onset, slowly progressive limb girdle muscular dystrophy. Neuromuscul Disord 1998;8:305–308.

e218. Melacini P, Fanin M, Duggan DJ, et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999;22:473–479.

e219. Vainzof M, Passos-Bueno MR, Canovas M, et al. The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum Mol Genet 1996;5:1963–1969.

e220. Spengos K, Walter MC, Dekomien G, Papadopoulos K, Lochmüller H, Manta P. C283Y mutation in the gamma-sarcoglycan gene in Greek Gypsies with severe limb girdle muscular dystrophy. Eur J Neurol 2010;17:e41–e42.

e221. Eymard B, Romero NB, Leturcq F, et al. Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. Neurology 1997;48(5):1227–1234.

e222. Vlak M, van der Kooi E, Angelini C. Correlation of clinical function and muscle CT scan images in limb-girdle muscular dystrophy. Neurol Sci 2000;21(5 Suppl):S975–S977.

e223. Hackman P, Juvonen V, Saraparanta J, et al. Enrichment of the R77C alpha-sarcoglycan gene mutation in Finnish LGMD2D patients. Muscle Nerve 2005;31(2):199–204.

e224. Fendri K, Kefi M, Hentati F, Amouri R. Genetic heterogeneity within a consanguineous family involving the LGMD 2D and the LGMD 2C genes. Neuromuscul Disord 2006;16(5):316–320.

e225. Vainzof M, Moreira ES, Canovas M, et al. Partial alpha-sarcoglycan deficiency with retention of the dystrophin-glycoprotein complex in a LGMD2D family. Muscle Nerve 2000;23:984–988.

e226. Piccolo F, Roberds SL, Jeanpierre M, et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat Genet 1995;10:243–245.

e227. Tétreault M, Srour M, Allyson J, et al. Founder mutation for α-sarcoglycan-LGMD2D in a Magdalen Islands Acadian cluster. Can J Neurol Sci 2011;38:747–752.

e228. Balci B, Wilichowski E, Haliloğlu G, et al. Beta-sarcoglycan gene mutations in Turkey. Acta Myol 2004;23(3):154–158.

e229. Bönnemann CG, Wong J, Ben Hamida C, Hamida MB, Hentati F, Kunkel LM. LGMD 2E in Tunisia is caused by a homozygous missense mutation in beta-sarcoglycan exon 3. Neuromuscul Disord 1998;8:193–197.

e230. Fanin M, Melacini P, Boito C, Pegoraro E, Angelini C. LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord 2003;13:303–309.

e231. Nigro V, de Sá Moreira E, Piluso G, et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet 1996;14:195–198.

e232. Moreira ES, Vainzof M, Marie SK, Sertié AL, Zatz M, Passos-Bueno MR. The seventh form of autosomal recessive limb-girdle muscular dystrophy is mapped to 17q11-12. Am J Hum Genet 1997;61:151–159.

e233. Moreira ES, Wiltshire TJ, Faulkner G, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 2000;24(2):163–166.

e234. Schoser BG, Frosk P, Engel AG, Klutzny U, Lochmüller H, Wrogemann K. Commonality of TRIM32 mutation in causing sarcotubular myopathy and LGMD2H. Ann Neurol 2005;57(4):591–595.

e235. Borg K, Stucka R, Locke M, et al. Intragenic deletion of TRIM32 in compound heterozygotes with sarcotubular myopathy/LGMD2H. Hum Mutat 2009;30(9):E831–E844.

e236. Saccone V, Palmieri M, Passamano L, et al. Mutations that impair interaction properties of TRIM32 associated with limb-girdle muscular dystrophy 2H. Hum Mutat 2008;29:240–247.

e237. Weiler T, Greenberg CR, Zelinski T, et al. A gene for autosomal recessive limb-girdle muscular dystrophy in Manitoba Hutterites maps to chromosome region 9q31-q33: evidence for another limb-girdle muscular dystrophy locus. Am J Hum Genet 1998;63:140–147.

e238. dePaula F, Vieira N, Starling A, et al. Asymptomatic carriers for homozygous novel mutations in the FKRP gene: the other end of the spectrum. Eur J Hum Genet 2003;11:923–930.

e239. Gaul C, Deschauer M, Tempelmann C, et al. Cardiac involvement in limb-girdle muscular dystrophy 2I: conventional cardiac diagnostic and cardiovascular magnetic resonance. J Neurol 2006;253:1317–1322.

e240. Bourteel H, Vermersch P, Cuisset JM, et al. Clinical and mutational spectrum of limb-girdle muscular dystrophy type 2I in 11 French patients. J Neurol Neurosurg Psychiatry 2009;80:1405–1408.

e241. Brown SC, Torelli S, Brockington M, et al. Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. Am J Pathol 2004;164:727–737.

e242. Driss A, Amouri R, Ben Hamida C, et al. A new locus for autosomal recessive limb-girdle muscular dystrophy in a large consanguineous Tunisian family maps to chromosome 19q13.3. Neuromuscul Disord 2000;10:240–246.

e243. Harel T, Goldberg Y, Shalev SA, Chervinski I, Ofir R, Birk OS. Limb-girdle muscular dystrophy 2I: phenotypic variability within a large consanguineous Bedouin family associated with a novel FKRP mutation. Eur J Hum Genet 2004;12:38–43.

e244. Jimenez-Mallebrera C, Torelli S, Feng L, et al. A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity. Brain Pathol 2009;19:596–611.

e245. Poppe M, Cree L, Bourke J, et al. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 2003;60:1246–1251.

e246. Sveen ML, Jeppesen TD, Hauerslev S, Krag TO, Vissing J. Endurance training: an effective and safe treatment for patients with LGMD2I. Neurology 2007;68(1):59–61.

e247. Wahbi K, Meune C, Hamouda el H, et al. Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. Neuromuscul Disord 2008;18:650–655.

e248. Kefi M, Amouri R, Chabrak S, Mechmeche R, Hentati F. Variable cardiac involvement in Tunisian siblings harboring FKRP gene mutations. Neuropediatrics 2008;39:113–115.

e249. Frosk P, Greenberg CR, Tennese AA, et al. The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. Hum Mutat 2005;25:38–44.

e250. Lindberg C, Sixt C, Oldfors A. Episodes of exercise-induced dark urine and myalgia in LGMD 2I. Acta Neurol Scand 2012;125:285–287.

e251. Mathews KD, Stephan CM, Laubenthal K, et al. Myoglobinuria and muscle pain are common in patients with limb-girdle muscular dystrophy 2I. Neurology 2011;76:194–195.

e252. Müller T, Krasnianski M, Witthaut R, Deschauer M, Zierz S. Dilated cardiomyopathy may be an early sign of the C826A Fukutin-related protein mutation. Neuromuscul Disord 2005;15:372–376.

e253. Palmieri A, Manara R, Bello L, et al. Cognitive profile and MRI findings in limb-girdle muscular dystrophy 2I. J Neurol 2011;258:1312–1320.

e254. Vieira NM, Schlesinger D, de Paula F, Vainzof M, Zatz M. Mutation analysis in the FKRP gene provides an explanation for a rare cause of intrafamilial clinical variability in LGMD2I. Neuromuscul Disord 2006;16:870–873.

e255. Yilmaz A, Gdynia HJ, Ponfick M, Ludolph AC, Rösch S, Sechtem U. The proteoglycan-dystrophin complex in genetic cardiomyopathies--lessons from three siblings with limb-girdle muscular dystrophy-2I (LGMD-2I). Clin Res Cardiol 2011;100:611–615.

e256. Mercuri E, Brockington M, Straub V, et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 2003;53:537–542.

e257. Walter MC, Petersen JA, Stucka R, et al. FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet 2004;41:e50.

e258. Udd B. Limb-girdle type muscular dystrophy in a large family with distal myopathy: homozygous manifestation of a dominant gene? J Med Genet 1992;29(6):383–389.

e259. Udd B, Rapola J, Nokelainen P, Arikawa E, Somer H. Nonvacuolar myopathy in a large family with both late adult onset distal myopathy and severe proximal muscular dystrophy. J Neurol Sci 1992;113(2):214–221.

e260. Udd B, Partanen J, Halonen P, et al. Tibial muscular dystrophy. Late adult-onset distal myopathy in 66 Finnish patients. Arch Neurol 1993;50(6):604-608.

e261. Udd B, Haravuori H, Kalimo H, et al. Tibial muscular dystrophy--from clinical description to linkage on chromosome 2q31. Neuromuscul Disord 1998;8(5):327–332.

e262. Van den Bergh PY, Bouquiaux O, Verellen C, et al. Tibial muscular dystrophy in a Belgian family. Ann Neurol 2003;54(2):248–251.

e263. Mahjneh I, Lamminen AE, Udd B, et al. Muscle magnetic resonance imaging shows distinct diagnostic patterns in Welander and tibial muscular dystrophy. Acta Neurol Scand 2004;110(2):87–93.

e264. Pénisson-Besnier I, Hackman P, Suominen T, et al. Myopathies caused by homozygous titin mutations: limb-girdle muscular dystrophy 2J and variations of phenotype. J Neurol Neurosurg Psychiatry 2010;81(11):1200–1202.

e265. Ohlsson M, Hedberg C, Brådvik B, et al. Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin. Brain 2012;135(Pt 6):1682–1694.

e266. Pfeffer G, Elliott HR, Griffin H, et al. Titin mutation segregates with hereditary myopathy with early respiratory failure. Brain 2012;135(Pt 6):1695–1713.

e267. Carmignac V, Salih MA, Quijano-Roy S, et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007;61:340–351.

e268. Udd B, Kääriänen H, Somer H. Muscular dystrophy with separate clinical phenotypes in a large family. Muscle Nerve 1991;14:1050–1058.

e269. Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010;86(2):213–221.

e270. Mahjneh I, Jaiswal J, Lamminen A, et al. A new distal myopathy with mutation in anoctamin 5. Neuromuscul Disord 2010;20(12):791–795.

e271. Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. Muscle Nerve 2012;45:740–742.

e272. Jaiswal JK, Marlow G, Summerill G, et al. Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect. Traffic 2007;8(1):77–88.

e273. Jarry J, Rioux MF, Bolduc V, et al. A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. Brain 2007;130(Pt 2):368–380.

e274. Godfrey C, Escolar D, Brockington M, et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 2006;60(5):603–610.

e275. Biancheri R, Falace A, Tessa A, et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun 2007;363(4):1033–1037.

e276. Clement EM, Godfrey C, Tan J, et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol 2008;65(1):137–141.

e277. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Eng J Med 2011;364:939–946.

e278. Dinçer P, Balci B, Yuva Y, et al. A novel form of recessive limb girdle muscular dystrophy with mental retardation and abnormal expression of α-dystroglycan. Neuromuscul Disord 2003;13:771–778.

e279. Banwell BL, Russel J, Fukudome T, Shen XM, Stilling G, Engel AG. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol 1999;58:832–846.

e280. Charlesworth A, Chiaverini C, Chevrant-Breton J, et al. Epidermolysis bullosa simplex with PLEC mutations: new phenotypes and new mutations [published online ahead of print Jan 5, 2013]. Br J Dermatol doi: 10.1111/bjd.12202.

e281. Chavanas S, Pulkkinen L, Gache Y, et al. A homozygous nonsense mutation in the PLEC1 gene in patients with epidermolysis bullosa simplex with muscular dystrophy. J Clin Invest 1996;98:2196–2200.

e282. Forrest K, Mellerio JE, Robb S, et al. Congenital muscular dystrophy, myasthenic symptoms and epidermolysis bullosa simplex (EBS) associated with mutations in the PLEC1 gene encoding plectin. Neuromuscul Disord 2010;20:709–711.

e283. Gache Y, Chavanas S, Lacour JP, et al. Defective expression of plectin/HD1 in epidermolysis bullosa simplex with muscular dystrophy. J Clin Invest 1996;97:2289–2298.

e284. Mellerio JE, Smith FJ, McMillian JR, et al. Recessive epidermolysis bullosa simplex associated with plectin mutations: infantile respiratory complications in two unrelated cases. Br J Dermatol 1997;137:898–906.

e285. Natsuga K, Nishie W, Shinkuma S, et al. Plectin deficiency leads to both muscular dystrophy and pyloric atresia in epidermolysis bullosa simplex. Hum Mutat 2010;31:E1687–E1698.

e286. Pulkkinen L, Smith FJ, Shimizu H, et al. Homozygous deletion mutations in the plectin gene (PLEC1) in patients with epidermolysis bullosa simplex associated with late-onset muscular dystrophy. Hum Mol Genet 1996;5:1539–1546.

e287. Rouan F, Pulkkinen L, Meneguzzi G, et al. Epidermolysis bullosa: novel and de novo premature termination codon and deletion mutations in the plectin gene predict late-onset muscular dystrophy. J Invest Dermatol 2000;114:381–387.

e288. Schara U, Tücke J, Mortier W, et al. Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation. Eur J Pediatr 2004;163:218–222.

e289. Schröder R, Kunz WS, Rouan F, et al. Disorganization of the desmin cytoskeleton and mitochondrial dysfunction in plectin-related epidermolysis bullosa simplex with muscular dystrophy. J Neuropathol Exp Neurol 2002;61:520–530.

e290. Smith FJ, Eady RA, Leigh IM, et al. Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. Nat Genet 1996;13:450–457.

e291. Takizawa Y, Shimizu H, Rouan F, et al. Four novel plectin gene mutations in Japanese patients with epidermolysis bullosa with muscular dystrophy disclosed by heteroduplex scanning and protein truncation tests. J Invest Dermatol 1999;112:109–112.

e292. Yiu EM, Klausegger A, Waddell LB, et al. Epidermolysis bullosa with late-onset muscular dystrophy and plectin deficiency. Muscle Nerve 2011;44:135–141.

e293. Selcen D, Juel VC, Hobson-Webb LD, et al. Myasthenic syndrome caused by plectinopathy. Neurology 2011;76:327–336.

e294. Shimizu H, Takizawa Y, Pulkkinen L, et al. Epidermolysis bullosa simplex associated with muscular dystrophy: phenotype-genotype correlations and review of the literature. J Am Acad Dermatol 1999;41:950–956.

e295. Takahashi Y, Rouan F, Uitto J, et al. Plectin deficient epidermolysis bullosa simplex with 27-year-history of muscular dystrophy. J Dermatol Sci 2005;37:87–93.

e296. Patrizi A, Di Lernia V, Neri I, Badiali De Giorgi L, Masi M. Epidermolysis bullosa simplex associated with muscular dystrophy: a new case. Pediatr Dermatol 1994;11:342–345.

e297. Niemi KM, Sommer H, Kero M, Kanerva L, Haltia M. Epidermolysis bullosa simplex associated with muscular dystrophy with recessive inheritance. Arch Dermatol 1988;124:551–554.

e298. Natsuga K, Nishie W, Akiyama M, et al. Plectin expression patterns determine two distinct subtypes of epidermolysis bullosa simplex. Hum Mutat 2010;31:308–316.

e299. Koss-Harnes, D, Jahnsen FL, Wiche G, Soyland E, Brandtzaeg P, Gedde-Dahl T Jr. Plectin abnormality in epidermolysis bullosa simplex Ogna: non-responsiveness of basal keratinocytes to some anti-rat plectin antibodies. Exp Dermatol 1997;6:41–48.

e300. Kunz M, Rouan F, Pulkkinen L, et al. Mutation reports: epidermolysis bullosa simplex associated with severe mucous membrane involvement and novel mutations in the plectin gene. J Invest Dermatol 2000;114:376–380.

e301. Kurose K, Mori O, Hachisuka H, Shimizu H, Owaribe K, Hashimoto T. Cultured keratinocytes from plectin/HD1-deficient epidermolysis bullosa simplex showed altered ability of adhesion to the matrix. J Dermatol Sci 2000;24:184–189.

e302. McLean WH, Pulkkinen L, Smith FJ, et al. Loss of plectin causes epidermolysis bullosa with muscular dystrophy: cDNA cloning and genomic organization. Genes Dev 1996;10:1724–1735.

e303. Maselli RA, Arredondo J, Cagney O, et al. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE. Clin Genet 2011;80:444–451.

e304. McMillan JR, Akiyama M, Rouan F, et al. Plectin defects in epidermolysis bullosa simplex with muscular dystrophy. Muscle Nerve 2007;35:24–35.

e305. Doriguzzi C, Palmucci L, Mongini T, et al. Congenital muscular dystrophy associated with familial junctional epidermolysis bullosa letalis. Eur Neurol 1993;33:454–460.

e306. Fine JD, Stenn J, Johnson L, Wright T, Bock HG, Horiguchi Y. Autosomal recessive epidermolysis bullosa simplex. Generalized phenotypic features suggestive of junctional or dystrophic epidermolysis bullosa, and association with neuromuscular diseases. Arch Dermatol 1989;125:931–938.

e307. Bolling MC, Pas HH, de Visser M, et al. PLEC1 mutations underlie adult-onset dilated cardiomyopathy in epidermolysis bullosa simplex with muscular dystrophy. J Invest Dermatol 2010;130:1178–1181.

e308. Dang M, Pulkkinen L, Smith FJ, McLean WH, Uitto J. Novel compound heterozygous mutations in the plectin gene in epidermolysis bullosa with muscular dystrophy and the use of protein truncation test for detection of premature termination codon mutations. Lab Invest 1998;78:195–204.

e309. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993;240:98–104.

e310. Bushby KM, Gardner-Medwin D, Nicholson LV, et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 1993;240:105–112.

e311. Bushby KM. Genetic and clinical correlations of Xp21 muscular dystrophy. J Inherit Metab Dis 1992;15:551–564.

e312. Agretto A, Politano L, Bossone E, et al. Pulsed Doppler tissue imaging in dystrophinopathic cardiomyopathy. J Am Soc Echocardiogr 2002;15:891–899.

e313. Ammendola E, Russo V, Politano L, Santangelo L, Calabrò R. Is heart rate variability a valid parameter to predict sudden death in patients with Becker’s muscular dystrophy? Heart 2006;92:1686–1687.

e314. Annuar AA, Wong KT, Ching AS, et al. Exercise induced cramps and myoglobinuria in dystrophinopathy--a report of three Malaysian patients. Neurol Asia 2010;15:125–131.

e315. Angelini C, Fanin M, Pegoraro E, Freda MP, Cadaldini M, Martinello F. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord 1994:4:349–358.

e316. Anthony K, Cirak S, Torelli S, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011;134:3547–3559.

e317. Arahata K, Hoffman EP, Kunkel LM, et al. Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses. Proc Natl Acad Sci U S A 1989;86:7154–7158.

e318. Bardoni A, Felisari G, Sironi M, et al. Loss of Dp140 regulatory sequences is associated with cognitive impairment in dystrophinopathies. Neuromuscul Disord 2000;10:194–199.

e319. Berlit P, Stegaru-Hellring B. The heart in muscular dystrophy: an electrocardiographic and ultrasound study of 20 patients. Eur Arch Psychiatry Clin Neurosci 1991;241:177–180.

e320. Carsana A, Frisso G, Tremolaterra MR, et al. Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. Ann Hum Genet 2005;69:253–259.

e321. Comi GP, Prelle A, Bresolin N, et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 1994;117:1–14.

e322. Comi LI, Nigro G, Politano L, Petretta VR. The cardiomyopathy of Duchenne/Becker consultands. Int J Cardiol 1992;34:297–305.

e323. Connuck DM, Sleeper LA, Colan SD, et al; Pedatric Cardiomyopathy Registry Study Group. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008;155:998–1005.

e324. de Visser M, de Voogt WG, la Rivière GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992;15:591–596.

e325. Finsterer J, Stöllberger C, Keller H, Slany J, Mamoli B. Cardiac involvement in patients with myotonic dystrophy, Becker’s muscular dystrophy and mitochondrial myopathy. Herz 1997;22:96–103.

e326. Gold R, Kress W, Meurers B, Meng G, Reichmann H, Müller CR. Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve 1992;15:214–218.

e327. de Visser M, Bakker E, Defesche JC, Bolhuis PA, van Ommen GJ. An unusual variant of Becker muscular dystrophy. Ann Neurol 1990;27:578–581.

e328. Hoogerwaard EM, de Voogt WG, Wilde AA, et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. J Neurol 1997;244:657–653.

e329. Jefferies JL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799–2804.

e330. Ginjaar IB, Kneppers AL, v d Meulen JD, et al. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. Eur J Hum Genet 2000;8:793–796.

e331. Gospe SM Jr, Lazaro RP, Lava NS, Grootscholten PM, Scott MO, Fischbeck KH. Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene. Neurology 1989;39:1277–1280.

e332. Mavrogeni S, Papavasiliou A, Skouteli E, Magoutas A, Dangas G. Cardiovascular magnetic resonance imaging evaluation of two families with Becker muscular dystrophy. Neuromuscul Disord 2010;20:717–719.

e333. Melacini P, Fanin M, Danieli GA, et al. Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol 1993;22:1927–1934.

e334. Melacini P, Fanin M, Danieli GA, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker’s muscular dystrophy. Circulation 1996;94:3168–3175.

e335. Melo M, Lauriano V, Gentil V, et al. Becker and limb-girdle muscular dystrophies: a psychiatric and intellectual level comparative study. Am J Med Genet 1995;60:33–38.

e336. Nicholson LV, Johnson MA, Bushby KM, et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. J Med Genet 1993;30:745–751.

e337. Nigro G, Comi LI, Politano L, et al. Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve 1995;18:283–291.

e338. Pradhan S. Valley sign in Becker muscular dystrophy and outliers of Duchenne and Becker muscular dystrophy. Neurol India 2004;52:203–205.

e339. Ramelli GP, Joncourt F, Luetschg J, Weis J, Tolnay M, Burgunder JM.. Becker muscular dystrophy with marked divergence between clinical and molecular genetic findings: case series. Swiss Med Wkly 2006;136:189–193.

e340. Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J 1996;132:642–647.

e341. Steare SE, Dubowitz V, Benatar A. Subclinical cardiomyopathy in Becker muscular dystrophy. Br Heart J 1992;68:304–308.

e342. Stöllberger C, Finsterer J, Keller H, Mamoli B, Slany J. Progression of cardiac involvement in patients with myotonic dystrophy, Becker’s muscular dystrophy and mitochondrial myopathy during a 2-year follow-up. Cardiology 1998;90:173–179.

e343. Matsumura K, Nonaka I, Tomé FM, et al. Mild deficiency of dystrophin-associated proteins in Becker muscular dystrophy patients having in-frame deletions in the rod domain of dystrophin. Am J Hum Genet 1993;53:409–416.

e344. Sveen ML, Jeppesen TD, Hauerslev S, Køber L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain 2008;131:2824–2831.

e345. Taşdemir HA, Cil E, Topaloğlu H, et al. Cardiorespiratory function in Duchenne and Becker muscular dystrophy. Turk J Pediatr 1996;38:307–314.

e346. Muntoni F, Mateddu A, Cianchetti C, et al. Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy. J Neurol Neurosurg Psychiatry 1993;56:26–31.

e347. Nakamura A, Yoshida K, Fukushima K, et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 2008;15:757–763.

e348. Nicholson LV, Johnson MA, Gardner-Medwin D, Bhattacharya S, Harris JB. Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. Acta Neuropathol 1990;80:239–250.

e349. Norman AM, Thomas NS, Kingston HM, Harper PS. Becker muscular dystrophy: correlation of deletion type with clinical severity. J Med Genet 1990;27:236–239.

e350. Yilmaz A, Gdynia HJ, Baccouche H, et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. J Cardiovasc Magn Reson 2008;10:50.

e351. Yoshida K, Ikeda S, Nakamura A, et al. Molecular analysis of the Duchenne muscular dystrophy gene in patients with Becker muscular dystrophy presenting with dilated cardiomyopathy. Muscle Nerve 1993;16:1161–1166.

e352. Young HK, Barton BA, Waisbren S, et al. Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol 2008;23:155–162.

e353. Zaidman CM, Connolly AM, Malkus EC, Florence JM, Pestronk A. Quantitative ultrasound using backscatter analysis in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 2010;20:805–809.

e354. Zatz M, Rapaport D, Vainzof M, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J Neurol Sci 1991;102:190–196.

e355. Yazaki M, Yoshida K, Nakamura A, et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999;42:145–149.

e356. Sahashi K, Ibi T, Suoh H, et al. Immunostaining of dystrophin and utrophin in skeletal muscle of dystrophinopathies. Intern Med 1994;33:277–283.

e357. Sánchez-Arjona MB, Rodríguez-Uranga JJ, Giles-Lima M, et al. Spanish family with myalgia and cramps syndrome. J Neurol Neurosurg Psychiatry 2005;76:286–289.

e358. Veerapandiyan A, Shashi V, Jiang YH, Gallentine WB, Schoch K, Smith EC. Pseudometabolic presentation of dystrophinopathy due to a missense mutation. Muscle Nerve 2010;42:975–979.

e359. Brabec P, Vondrácek P, Klimes D, et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscul Disord 2009;19:250–254.

e360. Sultan A, Fayaz M. Prevalence of cardiomyopathy in Duchenne and Becker’s muscular dystrophy. J Ayub Med Coll Abbottabad 2008;20:7–13.

e361. Arahata K, Ishihara T, Kamakura K, et al. Mosaic expression of dystrophin in symptomatic carriers of Duchenne’s muscular dystrophy. N Engl J Med 1989;320:138–142.

e362. Azofeifa J, Voit T, Hübner C, Cremer M. X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes. Hum Genet 1995;96:167–176.

e363. Bushby KM, Goodship JA, Nicholson LV, Johnson MA, Haggerty ID, Gardner-Medwin D. Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1993;3:57–64.

e364. Golla S, Agadi S, Burns DK, et al. Dystrophinopathy in girls with limb girdle muscular dystrophy phenotype. J Clin Neuromuscul Disord 2010;11:203–208.

e365. Grain L, Cortina-Borja M, Forfar C, Hilton-Jones D, Hopkin J, Burch M. Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls. Neuromuscul Disord 2001;11:186–191.

e366. Hoogerwaard EM, Bakker E, Ippel PF, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999;353:2116–2119.

e367. Hoogerwaard EM, van der Wouw PA, Wilde AA, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1999;9:347–351.

e368. Pikó H, Vancsó V, Nagy B, Bán Z, Herczegfalvi A, Karcagi V. Dystrophin gene analysis in Hungarian Duchenne/Becker muscular dystrophy families - detection of carrier status in symptomatic and asymptomatic female relatives. Neuromuscul Disord 2009;19:108–112.

e369. Politano L, Nigro V, Nigro G, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 1996;275:1335–1338.

e370. Soltanzadeh P, Friez MJ, Dunn D, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord 2010;20:499–504.

e371. Minetti C, Chang HW, Medori R, et al. Dystrophin deficiency in young girls with sporadic myopathy and normal karyotype. Neurology 1991;41:1288–1292.

e372. Seemann N, Selby K, McAdam L, et al; Canadian Pediatric Neuromuscular Group. Symptomatic dystrophinopathies in female children. Neuromuscul Disord 2011;21:172–177.

e373. Bialer MG, McDaniel NL, Kelly TE. Progression of cardiac disease in Emery-Dreifuss muscular dystrophy. Clin Cardiol 1991;14:411–416.

e374. Bialer MG, Bruns DE, Kelly TE. Muscle enzymes and isoenzymes in Emery-Dreifuss muscular dystrophy. Clin Chem 1990;36:427–430.

e375. Buckley AE, Dean J, Mahy IR. Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series. Heart 1999;82:105–108.

e376. Canki-Klain N, Récan D, Milicić D, et al. Clinical variability and molecular diagnosis in a four-generation family with X-linked Emery-Dreifuss muscular dystrophy. Croat Med J 2000;41:389–395.

e377. Carboni N, Mura M, Mercuri E, et al. Cardiac and muscle imaging findings in a family with X-linked Emery-Dreifuss muscular dystrophy. Neuromuscul Disord 2012;22:152–158.

e378. Draminska A, Kuch-Wocial A, Szulc M, et al. Echocardiographic assessment of left ventricular morphology and function in patients with Emery-Dreifuss muscular dystrophy. Int J Cardiol 2005;102:207–210.

e379. Fidziańska A, Rowińska-Marcińska K, Hausmanowa-Petrusewicz I. Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol 2004;107:197–203.

e380. Menache CC, Brown CA, Donnelly JH, Shapiro F, Darras BT. Identification of a novel truncating mutation (S171X) in the Emerin gene in five members of a Caucasian American family with Emery-Dreifuss muscular dystrophy. Hum Mutat 2000;16:94.

e381. Karst ML, Herron KJ, Olson TM. X-linked nonsyndromic sinus node dysfunction and atrial fibrillation caused by emerin mutation. J Cardiovasc Electrophysiol 2008;19:510–515.

e382. Mora M, Cartegni L, Di Blasi C, et al. X-linked Emery-Dreifuss muscular dystrophy can be diagnosed from skin biopsy or blood sample. Ann Neurol 1997;42:249–253.

e383. Sakata K, Shimizu M, Ino H, et al. High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. Circulation 2005;111:3352–3358.

e384. Knoblauch H, Geier C, Adams S, et al. Contractures and hypertrophic cardiomyopathy in a novel FHL1 mutation. Ann Neurol 2010;67:136–140.

e385. Quinzii CM, Vu TH, Min KC, et al. X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1. Am J Hum Genet 2008;82:208–213.

e386. Schessl J, Columbus A, Hu Y, et al. Familial reducing body myopathy with cytoplasmic bodies and rigid spine revisited: identification of a second LIM domain mutation in FHL1. Neuropediatrics 2010;41:43–46.

e387. Schessl J, Taratuto AL, Sewry C, et al. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1. Brain 2009;132:452–464.

e388. Schoser B, Goebel HH, Janisch I, et al. Consequences of mutations within the C terminus of the FHL1 gene. Neurology 2009;73:543–551.

e389. Shalaby S, Hayashi YK, Nonaka I, Noguchi S, Nishino I. Novel FHL1 mutations in fatal and benign reducing body myopathy. Neurology 2009;72:375–376.

e390. Chen DH, Raskind WH, Parson WW, et al. A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations. J Neurol Sci 2010;296:22–29.

e391. Schessl J, Zou Y, McGrath MJ, et al. Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy. J Clin Invest 2008;118:904–912.

e392. Selcen D, Bromberg MB, Chin SS, Engel AG. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. Neurology 2011;77:1951–1959.

e393. Sarkozy A, Windpassinger C, Hudson J, et al. Phenotypic heterogeneity in British patients with a founder mutation in the FHL1 gene. Eur J Hum Genet 2011;19:1038–1044.

e394. Shalaby S, Hayashi YK, Goto K, et al. Rigid spine syndrome caused by a novel mutation in four-and-a-half LIM domain 1 gene (FHL1). Neuromuscul Disord 2008;18:959–961.

e395. Nakano S, Engel AG, Waclawik AJ, Emslie-Smith AM, Busis NA. Myofibrillar myopathy with abnormal foci of desmin positivity. I. Light and electron microscopy analysis of 10 cases. J Neuropathol Exp Neurol 1996;55:549–562.

e396. De Bleecker JL, Engel AG, Ertl BB. Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins. J Neuropathol Exp Neurol 1996;55:563–577.

e397. Claeys KG, van der Ven PF, Behin A, et al. Differential involvement of sarcomeric proteins in myofibrillar myopathies: a morphological and immunohistochemical study. Acta Neuropathol 2009;117:293–307.

e398. Claeys KG, Fardeau M, Schröder R, et al. Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. Neuromuscul Disord 2008;18:656–666.

e399. Berciano J, Gallardo E, Domínguez-Perles R, et al. Autosomal-dominant distal myopathy with a myotilin S55F mutation: sorting out the phenotype. J Neurol Neurosurg Psychiatry 2008;79:205–208.

e400. Fischer D, Kley RA, Strach K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 2008;71:758–765.

e401. Foroud T, Pankratz N, Batchman AP, et al. A mutation in myotilin causes spheroid body myopathy. Neurology 2005;65:1936–1940.

e402. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000;9:2141–2147.

e403. Olivé M, Goldfarb LG, Shatunov A, Fischer D, Ferrer I. Myotilinopathy: refining the clinical and myopathological phenotype. Brain 2005;128:2315–2326.

e404. Pénisson-Besnier I, Talvinen K, Dumez C, et al. Myotilinopathy in a family with late onset myopathy. Neuromuscul Disord 2006;16:427–431.

e405. Schramm N, Born C, Weckbach S, Reilich P, Walter MC, Reiser MF. Involvement patterns in myotilinopathy and desminopathy detected by a novel neuromuscular whole-body MRI protocol. Eur Radiol 2008;18:2922–2936.

e406. Olivé M, Odgerel Z, Martínez A, et al. Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy. Neuromuscul Disord 2011;21:533–542.

e407. Gilchrist JM, Pericak-Vance M, Silverman L, Roses AD. Clinical and genetic investigation in autosomal dominant limb-girdle muscular dystrophy. Neurology 1988;38:5–9.

e408. Goldfarb LG, Park KY, Cervenáková L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998;19:402–403.

e409. Arias M, Pardo J, Blanco-Arias P, et al. Distinct phenotypic features and gender-specific disease manifestations in a Spanish family with desmin L370P mutation. Neuromuscul Disord 2006;16:498–503.

e410. Bergman JE, Veenstra-Knol HE, van Essen AJ, et al. Two related Dutch families with a clinically variable presentation of cardioskeletal myopathy caused by a novel S13F mutation in the desmin gene. Eur J Med Genet 2007;50:355–366.

e411. Dalakas MC, Dagvadorj A, Goudeau B, et al. Progressive skeletal myopathy, a phenotypic variant of desmin myopathy associated with desmin mutations. Neuromuscul Disord 2003;13:252–258.

e412. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000;342:770–780.

e413. Walter MC, Reilich P, Huebner A, et al. Scapuloperoneal syndrome type Kaeser and a wide phenotypic spectrum of adult-onset, dominant myopathies are associated with the desmin mutation R350P. Brain 2007;130:1485–1496.

e414. Goudeau B, Rodrigues-Lima F, Fischer D, et al. Variable pathogenic potentials of mutations located in the desmin alpha-helical domain. Hum Mutat 2006;27:906–913.

e415. Bär H, Goudeau B, Wälde S, et al. Conspicuous involvement of desmin tail mutations in diverse cardiac and skeletal myopathies. Hum Mutat 2007;28:374–376.

e416. Dagvadorj A, Olivé M, Urtizberea JA, et al. A series of West European patients with severe cardiac and skeletal myopathy associated with a de novo R406W mutation in desmin. J Neurol 2004;251:143–149.

e417. Olivé M, Armstrong J, Miralles F, et al. Phenotypic patterns of desminopathy associated with three novel mutations in the desmin gene. Neuromuscul Disord 2007;17:443–450.

e418. Hong D, Wang Z, Zhang W, et al. A series of Chinese patients with desminopathy associated with six novel and one reported mutations in the desmin gene. Neuropathol Appl Neurobiol 2011;37:257–270.

e419. Greenberg SA, Salajegheh M, Judge DP, et al. Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Ann Neurol 2012;71:141–145.

e420. Vernengo L, Chourbagi O, Panuncio A, et al. Desmin myopathy with severe cardiomyopathy in a Uruguayan family due to a codon deletion in a new location within the desmin 1A rod domain. Neuromuscul Disord 2010;20:178–187.

e421. Melberg A, Oldfors A, Blomström-Lundqvist C, et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. Ann Neurol 1999;46:684–692.

e422. Reilich P, Schoser B, Schramm N, et al. The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. Neuromuscul Disord 2010;20:255–259.

e423. Selcen D, Engel AG. Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. Ann Neurol 2003;54:804–810.

e424. Sacconi S, Féasson L, Antoine JC, et al. A novel CRYAB mutation resulting in multisystemic disease. Neuromuscul Disord 2012;22:66–72.

e425. Griggs R, Vihola A, Hackman P, et al. Zaspopathy in a large classic late-onset distal myopathy family. Brain 2007;130:1477–1484.

e426. Odgerel Z, Sarkozy A, Lee HS, et al. Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. Neuromuscul Disord 2010;20:438–442.

e427. Vorgerd M, van der Ven PF, Bruchertseifer V, et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am J Hum Genet 2005;77:297–304.

e428. Kley RA, Hellenbroich Y, van der Ven PF, et al. Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients. Brain 2007;130:3250–3264.

e429. Williams DR, Reardon K, Roberts L, et al. A new dominant distal myopathy affecting posterior leg and anterior upper limb muscles. Neurology 2005;64:1245–1254.

e430. Duff RM, Tay V, Hackman P, et al. Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy. Am J Hum Genet 2011;88:729–740.

e431. Guergueltcheva V, Peeters K, Baets J, et al. Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. Neurology 2011;77:2105–2114.

e432. Luan X, Hong D, Zhang W, Wang Z, Yuan Y. A novel heterozygous deletion-insertion mutation (2695-2712 del/GTTTGT ins) in exon 18 of the filamin C gene causes filaminopathy in a large Chinese family. Neuromuscul Disord 2010;20:390–396.

e433. Chai Y, Bertorini TE, McGrew FA. Hereditary inclusion-body myopathy associated with cardiomyopathy: report of two siblings. Muscle Nerve 2011;43:133–136.

e434. Mitrani-Rosenbaum S, Argov Z, Blumenfeld A, Seidman CE, Seidman JG. Hereditary inclusion body myopathy maps to chromosome 9p1-q1. Hum Mol Genet 1996;5:159–163.

e435. Adler RS, Garolfalo G, Paget S, Kagen L. Muscle sonography in six patients with hereditary inclusion body myopathy. Skeletal Radiol 2008;37:43–48.

e436. Argov Z, Eisenberg I, Grabov-Nardini G, et al. Hereditary inclusion body myopathy: the Middle Eastern genetic cluster. Neurology 2003;60:1519–1523.

e437. Kim BJ, Ki CS, Kim JW, Sung DH, Choi YC, Kim SH. Mutation analysis of the GNE gene in Korean patients with distal myopathy with rimmed vacuoles. J Hum Genet 2006;51:137–140.

e438. Li H, Chen Q, Liu F, et al. Clinical and molecular genetic analysis in Chinese patients with distal myopathy with rimmed vacuoles. J Hum Genet 2011;56:335–338.

e439. Lu X, Pu C, Huang X, Liu J, Mao Y. Distal myopathy with rimmed vacuoles: clinical and muscle morphological characteristics and spectrum of GNE gene mutations in 53 Chinese patients. Neurol Res 2011;33:1025–1031.

e440. Mori-Yoshimura M, Monma K, Suzuki N, et al. Heterozygous UDP-GlcNAc 2-epimerase and N-acetylmannosamine kinase domain mutations in the GNE gene result in a less severe GNE myopathy phenotype compared to homozygous N-acetylmannosamine kinase domain mutations. J Neurol Sci 2012;318:100–105.

e441. Argov Z, Yarom R. “Rimmed vacuole myopathy” sparing the quadriceps. A unique disorder in Iranian Jews. J Neurol Sci 1984;64:33–43.

e442. Nonaka I, Sunohara N, Ishiura S, Satoyoshi E. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. J Neurol Sci 1981;51:141–155.

e443. Nonaka I, Sunohara N, Satoyoshi E, Terasawa K, Yonemoto K. Autosomal recessive distal muscular dystrophy: a comparative study with distal myopathy with rimmed vacuole formation. Ann Neurol 1985;17:51–59.

e444. Sadeh M, Gadoth N, Hadar H, Ben-David E. Vacuolar myopathy sparing the quadriceps. Brain 1993;116:217–232.

e445. Farpour F, Tehranzadeh J, Donkervoort S, et al. Radiological features of Paget disease of bone associated with VCP myopathy. Skeletal Radiol 2012;41:329–337.

e446. Kimonis VE, Kovach MJ, Waggoner B, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med 2000;2:232–241.

e447. Kimonis VE, Mehta SG, Fulchiero EC, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A 2008;146A:745–757.

e448. Kimonis VE, Watts GD. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord 2005;19 Suppl 1:S44–S47.

e449. Guyant-Maréchal L, Laquierrière A, Duyckaerts C, et al. Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology 2006;67:644–651.

e450. Haubenberger D, Bittner RE, Rauch-Shorny S, et al. Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology 2005;65:1304–1305.

e451. Miller TD, Jackson AP, Barresi R, et al. Inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD): clinical features including sphincter disturbance in a large pedigree. J Neurol Neurosurg Psychiatry 2009;80:583–584.

e452. Kim EJ, Park YE, Kim DS, et al. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family. Arch Neurol 2011;68:787–796.

e453. Kumar KR, Needham M, Mina K, et al. Two Australian families with inclusion-body myopathy, Paget’s disease of bone and frontotemporal dementia: novel clinical and genetic findings. Neuromuscul Disord 2010;20:330–334.

e454. Stojkovic T, Hammouda el H, Richard P, et al. Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget’s disease of bone and frontotemporal dementia. Neuromuscul Disord 2009;19:316–323.

e455. Viassolo V, Previtali SC, Schiatti E, et al. Inclusion body myopathy, Paget’s disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling. Clin Genet 2008;74:54–60.

e456. Waggoner B, Kovach MJ, Winkelman M, et al. Heterogeneity in familial dominant Paget disease of bone and muscular dystrophy. Am J Med Genet 2002;108:187–191.

e457. Watts GD, Thomasova D, Ramdeen SK, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 2007;72:420–426.

e458. Shi Z, Hayashi YK, Mitsuhashi S, et al. Characterization of the Asian myopathy patients with VCP mutations. Eur J Neurol 2012;19:501–509.

e459. van der Zee J, Pirici D, Van Langenhove T, et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology 2009;73:626–632.

e460. Watts GD. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36:377–381.

e461. Palmio J, Sandell S, Suominen T, et al. Distinct distal myopathy phenotype caused by VCP gene mutation in a Finnish family. Neuromuscul Disord 2011;21:551–555.

e462. Sunnerhagen KS, Darin N, Tajsharghi H, Oldfors A. The effects of endurance training in persons with a hereditary myosin myopathy. Acta Neurol Scand 2004;110:80–86.

e463. Tajsharghi H, Darin N, Rekabdar E, et al. Mutations and sequence variation in the human myosin heavy chain IIa gene (MYH2). Eur J Hum Genet 2005;13:617–622.

e464. Tajsharghi H, Hilton-Jones D, Raheem O, Saukkonen AM, Oldfors A, Udd B. Human disease caused by loss of fast IIa myosin heavy chain due to recessive MYH2 mutations. Brain 2010;133:1451–1459.

e465. Tajsharghi H, Sunnerhagen KS, Darin N, Kyllerman M, Oldfors A. Induced shift in myosin heavy chain expression in myosin myopathy by endurance training. J Neurol 2004;251:179–183.

e466. Martinsson T, Oldfors A, Darin N, et al. Autosomal dominant myopathy: missense mutation (Glu-706 --> Lys) in the myosin heavy chain IIa gene. Proc Natl Acad Sci U S A 2000;97:14614–14619.

e467. Ahlberg G, Jakobsson F, Fransson A, Moritz A, Borg K, Edström L. Distribution of muscle degeneration in Welander distal myopathy--a magnetic resonance imaging and muscle biopsy study. Neuromuscul Disord 1994;4:55–62.

e468. Borg K, Ahlberg G, Borg J, Edström L. Welander’s distal myopathy: clinical, neurophysiological and muscle biopsy observations in young and middle aged adults with early symptoms. J Neurol Neurosurg Psychiatry 1991;54:494–498.

e469. Borg K, Solders G, Borg J, Edström L, Kristensson K. Neurogenic involvement in distal myopathy (Welander). Histochemical and morphological observations on muscle and nerve biopsies. J Neurol Sci 1989;91:53–70.

e470. Borg K, Tomé FM, Edström L. Intranuclear and cytoplasmic filamentous inclusions in distal myopathy (Welander). Acta Neuropathol 1991;82:102–106.

e471. von Tell D, Somer H, Udd B, Edström L, Borg K, Ahlberg G. Welander distal myopathy outside the Swedish population: phenotype and genotype. Neuromuscul Disord 2002;12:544–547.

e472. Hackman P, Sarparanta J, Lehtinen S, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1 [published online ahead of print Dec 13, 2012]. Ann Neurol doi: 10.1002/ana.23831.

e473. Bohlega S, Abu-Amero SN, Wakil SM, et al. Mutation of the slow myosin heavy chain rod domain underlies hyaline body myopathy. Neurology 2004;62:518–521.

e474. Dubourg O, Maisonobe T, Behin A, et al. A novel MYH7 mutation occurring independently in French and Norwegian Laing distal myopathy families and de novo in one Finnish patient. J Neurol 2011;258:1157–1163.

e475. Mastaglia FL, Phillips BA, Cala LA, et al. Early onset chromosome 14-linked distal myopathy (Laing). Neuromuscul Disord 2002;12:350–357.

e476. Meredith C, Herrmann R, Parry C, et al. Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause laing early-onset distal myopathy (MPD1). Am J Hum Genet 2004;75:703–708.

e477. Muelas N, Hackman P, Lugue H, et al. MYH7 gene tail mutation causing myopathic profiles beyond Laing distal myopathy. Neurology 2010;75:732–741.

e478. Laing NG, Laing BA, Meredith C, et al. Autosomal dominant distal myopathy: linkage to chromosome 14. Am J Hum Genet 1995;56:422–427.

e479. Masuzugawa S, Kuzuhara S, Narita Y, Naito Y, Taniguchi A, Ibi T. Autosomal dominant hyaline body myopathy presenting as scapuloperoneal syndrome: clinical features and muscle pathology. Neurology 1997;48:253–257.

e480. Overeem S, Schelhaas HJ, Blijham PJ, et al. Symptomatic distal myopathy with cardiomyopathy due to a MYH7 mutation. Neuromuscul Disord 2007;17:490–493.

e481. Tajsharghi H, Oldfors A, Macleod DP, Swash M. Homozygous mutation in MYH7 in myosin storage myopathy and cardiomyopathy. Neurology 2007;68:962.

e482. Tajsharghi H, Thornell LE, Lindberg C, Lindvall B, Henriksson KG, Oldfors A. Myosin storage myopathy associated with a heterozygous missense mutation in MYH7. Ann Neurol 2003;54:494–500.

e483. Tasca G, Ricci E, Penttilä S, et al. New phenotype and pathology features in MYH7-related distal myopathy. Neuromuscul Disord 2012;22:640–647.

e484. Feit H, Silbergleit A, Schneider LB, et al. Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. Am J Hum Genet 1998;63:1732–1742.

e485. Senderek J, Garvey SM, Krieger M, et al. Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am J Hum Genet 2009;84:511–518.

e486. Wallgren-Pettersson C, Lehtokari VL, Kalimo H, et al. Distal myopathy caused by homozygous missense mutations in the nebulin gene. Brain 2007;130:1465–1476.

e487. Lehtokari VL, Pelin K, Herczegfalvi A, et al. Nemaline myopathy caused by mutations in the nebulin gene may present as a distal myopathy. Neuromuscul Disord 2011;21:556–562.

e488. Cirak S, von Deimling F, Sachdev S, et al. Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. Brain 2010;133:2123–2135.

e489. Scoto M, Cirak S, Mein R, et al. SEPN1-related myopathies: clinical course in a large cohort of patients. Neurology 2011;76:2073–2078.

e490. Hayashi YK, Matsuda C, Ogawa M, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 2009;119:2623–2633.

e491. Rajab A, Straub V, McCann LJ, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet 2010;6(3):e1000874.

e492. Shastry S, Delgado MR, Dirik E, Turkmen M, Agarwal AK, Garg A. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am J Med Genet A 2010;152A(9):2245–2253.

e493. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63(5):561–571.

e494. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010;68(5):629–638.

e495. Bäckman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1995;5(3):233–241.

e496. Neumeyer AM, Cros D, McKenna-Yasek D, et al. Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. Neurology 1998;51(2):589–592.

e497. Cittadini A, Ines Comi L, Longobardi S, et al. A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. Eur Heart J 2003;24(7):664–672.

e498. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 2009;66(3):290–297.

e499. Sandin-aldehag A, Jonsson H. Evaluation of a hand training programme for patients with Welander distal myopathy. Scand J Occup Ther 2003;10:188–192.

e500. Herson S, Hentati F, Rigolet A, et al. A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain 2012;135:483–492.

e501. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1218–1226.

e502. Prater SN, Banugaria SG, DeArmey SM, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 2012;14(9):800–810.

e503. Barba-Romero MA, Barrot E, Bautista-Lorite J, et al. Clinical guidelines for late-onset Pompe disease. Rev Neurol 2012;54(8);497–507.

e504. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm 2012;9(11):1890–1895.

e505. Kwon HW, Kwon BS, Kim GB, et al. The effect of enalapril and carvedilol on left ventricular dysfunction in middle childhood and adolescent patients with muscular dystrophy. Korean Circ J 2012;42(3):184–191.

e506. Bushby K, Finkel R, Birnkrant DJ, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9(2):177–189.

e507. Allen HD, Thrush PT, Hoffman TM, Flanigan KM, Mendell JR. Cardiac management in neuromuscular diseases. Phys Med Rehabil Clin N Am 2012;23(4):855–868.

e508. Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG. Hereditary muscular dystrophies and the heart. Neuromuscul Disord 2010;20(8):479–492.

e509. Pane M, Messina S, Vasco G, et al. Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. Neuromuscul Disord 2012;22(8):685–689.

e510. Reardon CC, Christiansen D, Barnett ED, Cabral HJ. Intrapulmonary percussive ventilation vs incentive spirometry for children with neuromuscular disease. Arch Pediatr Adolesc Med 2005;159(6):526–531.

e511. Mills B, Bach JR, Zhao C, Saporito L, Sabharwal S. Posterior spinal fusion in children with flaccid neuromuscular scoliosis: the role of noninvasive positive pressure ventilatory support. J Pediatr Orthop 2013;33(5):488–493.

e512. Bowen RE, Abel MF, Arlet V, et al. Outcome assessment in neuromuscular spinal deformity. J Pediatr Orthop 2012;32(8):792–798.

e513. Mercado E, Alman B, Wright JB. Does spinal fusion influence quality of life in neuromuscular scoliosis? Spine (Phila Pa 1976) 2007;32(19 Suppl):S120–S125.

e514. Bridges CB, Woods L, Coyne-Beasley T; Centers for Disease Control and Prevention ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013;62(Suppl 1):9–19.

e515. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1227–1233.

e516. Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM. Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1993;74(7):711–715.

e517. Kilmer DD, McCrory MA, Wright NC, Aitkens SG, Bernauer EM. The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1994;75(5):560–563.

e518. Wright NC, Kilmer DD, McCrory MA, Aitkens, SG, Holcomb BJ, Bernauer EM. Aerobic walking in slowly progressive neuromuscular disease: effect of a 12-week program. Arch Phys Med Rehabil 1996;77(1):64–69.